TAD 600 is an injectable glutathione preparation containing 600 mg reduced L-glutathione per 4 ml vial, manufactured by Biomedica Foscama. It supports hepatoprotective processes, promotes cellular detoxification and acts as a potent endogenous antioxidant – particularly relevant under elevated liver stress caused by anabolic substances. ---
TAD 600 is a pharmaceutically manufactured, injectable glutathione preparation containing 600 mg of reduced L-glutathione (GSH) in 4 ml of solution per vial, produced by Biomedica Foscama under GMP-compliant manufacturing. The active substance represents the most important endogenous tripeptide antioxidant in the human organism and is involved in central processes of cellular detoxification, redox equilibrium
> Note: All dosage details are provided for informational purposes only. Individual use is the sole responsibility of medically qualified healthcare professionals. ---
| Phase | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| On-Cycle (during AAS) | 600 mg (1 vial) | 3× per week | i.m. or i.v. | Recommended alongside oral 17-aa steroids |
| Peak Load | 600 mg (1 vial) | Daily (5–7 days) | i.v. (slow) | When liver values are markedly elevated (ALT/AST >3× ULN) |
| Post-Cycle / PCT | 600 mg (1 vial) | 2–3× per week | i.m. | Adjunct to clomiphene or tamoxifen |
| Maintenance Phase | 600 mg (1 vial) | 1× per week | i.m. | Long-term antioxidant support |
TAD 600 is a pharmaceutically manufactured injectable glutathione preparation containing 600 mg reduced L-glutathione (GSH) in 4 ml solution per vial, produced by Biomedica Foscama under GMP-compliant conditions. The active substance represents the most important endogenous tripeptide antioxidant in the human body and is involved in central processes of cellular detoxification, redox balance and hepatic metabolism.
L-Glutathione (γ-L-glutamyl-L-cysteinyl-glycine) neutralises reactive oxygen species (ROS) through direct electron donation and serves as an essential co-substrate for glutathione peroxidase (GPx). Hepatocytes metabolise anabolic androgenic steroids (AAS) via CYP450 enzymes, generating electrophilic intermediate products that require GSH-dependent glutathione S-transferases (GST) for conjugation and renal excretion. TAD 600 provides exogenously available, already-reduced GSH, thereby bypassing intracellular de novo synthesis, which can become limited under oxidative stress. Studies demonstrate that intravenously administered L-glutathione significantly raises hepatic GSH concentrations and can measurably reduce markers such as ALT and AST. Parenteral administration (i.m./i.v.) ensures near-complete bioavailability, as oral glutathione undergoes extensive hydrolysis in the gastrointestinal tract.
Oral 17-alpha-alkylated steroids and high-dose injectable AAS protocols place considerable demands on hepatic biotransformation capacity. TAD 600 is used in this context to maintain glutathione homeostasis, reduce oxidative liver stress and accelerate the regeneration phase following a cycle. Administration takes place after reconstitution with a suitable solvent (water for injections, Ph. Eur.) and is possible both intramuscularly and intravenously. Each pack contains 10 vials, sufficient for a structured protocol period of two to four weeks. Product quality is assured through HPLC purity analysis and GMP batch release, guaranteeing a reproducible active substance concentration of ≥99% L-glutathione.
Each vial contains 600 mg reduced L-glutathione in lyophilised or liquid form for parenteral reconstitution. The formulation meets the requirements of the European Pharmacopoeia (Ph. Eur.) with regard to purity, sterility and freedom from pyrogens. Biomedica Foscama employs closed aseptic filling lines and batch traceability in accordance with EU GMP guidelines. TAD 600 contains no anabolic or hormonally active substances and is designed exclusively as a supportive and adjunct preparation.
---
Biomedica Foscama is an Italian pharmaceutical company with long-standing specialisation in parenteral amino acid and peptide preparations. The company manufactures TAD 600 under EU GMP-compliant conditions with full batch traceability and HPLC quality control. Biomedica Foscama's glutathione line is among the established reference products in European specialist circles for hepatoprotective infusion therapies. The production facilities meet the European Pharmacopoeia requirements for sterility and freedom from pyrogens. ---
| Brand | Biomedica Foscama |
|---|---|
| Active ingredient | glutathione |
| Also known as | Glutathion, GSH, reduziertes L-Glutathion, TAD 600, Biomedica Foscama Glutathion |
| Strength | 600 mg |
| Form | Vial |
| Pack size | 10 pieces |
| Item number | OTHER-GLUT-BIO-001 |
No reviews yet. Be the first to review this product.
Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.
Community FavoriteDMAA Rapid is an oral stimulant from Knoll Pharmaceuticals delivering 50 mg of 1,3-Dimethylamylamine (DMAA) per tablet. The product is aimed at athletes in a bodybuilding context who want targeted support for focus, energy availability and thermogenic effect before training.
Practitioner RecommendedReusable Pen is a reusable, mechanical injection device for standard 3 ml cartridges, enabling precise, incremental dosing of peptides, HGH and other active substances. The device features an integrated needle guard, is designed for multiple uses and meets the hygiene requirements of the medical profession.
Pairs well with these products.
High ConcentrationQuant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.
Long-Acting FormulaBolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.
Brand QualityEquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.
Pro ChoiceDragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.